BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ash Z, Emery P. The role of tocilizumab in the management of rheumatoid arthritis. Expert Opin Biol Ther. 2012;12:1277-1289. [PMID: 22849354 DOI: 10.1517/14712598.2012.707178] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Ishii M. Immunology proves a great success for treating systemic autoimmune diseases - a perspective on immunopharmacology: IUPHAR Review 23. Br J Pharmacol 2017;174:1875-80. [PMID: 28299772 DOI: 10.1111/bph.13784] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
2 Md Yusof MY, Emery P. Targeting interleukin-6 in rheumatoid arthritis. Drugs 2013;73:341-56. [PMID: 23456676 DOI: 10.1007/s40265-013-0018-2] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 6.6] [Reference Citation Analysis]
3 Rusconi M, Gerardi F, Santus W, Lizio A, Sansone VA, Lunetta C, Zanoni I, Granucci F. Inflammatory role of dendritic cells in Amyotrophic Lateral Sclerosis revealed by an analysis of patients' peripheral blood. Sci Rep 2017;7:7853. [PMID: 28798369 DOI: 10.1038/s41598-017-08233-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
4 Cardoso PRG, Matias KA, Dantas AT, Marques CDL, Pereira MC, Duarte ALBP, Rego MJBM, Pitta IDR, Pitta MGDR. Losartan, but not Enalapril and Valsartan, Inhibits the Expression of IFN-γ, IL-6, IL-17F and IL-22 in PBMCs from Rheumatoid Arthritis Patients. Open Rheumatol J 2018;12:160-70. [PMID: 30288187 DOI: 10.2174/1874312901812010160] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
5 Boniface K. Role of Th17 cells in the pathogenesis of rheumatoid arthritis. WJR 2013;3:25. [DOI: 10.5499/wjr.v3.i3.25] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Besada E. Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review. Patient Prefer Adherence 2014;8:1051-9. [PMID: 25120354 DOI: 10.2147/PPA.S34958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Wang H, Zhao J, Zhang H, Huang Y, Wang S, Tu Q, Yang N. CARD11 blockade suppresses murine collagen-induced arthritis via inhibiting CARD11/Bcl10 assembly and T helper type 17 response. Clin Exp Immunol 2014;176:238-45. [PMID: 24443940 DOI: 10.1111/cei.12275] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
8 Yang M, Cen X, Xie Q, Zuo C, Shi G, Yin G. Serum interleukin-6 expression level and its clinical significance in patients with dermatomyositis. Clin Dev Immunol 2013;2013:717808. [PMID: 24082909 DOI: 10.1155/2013/717808] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
9 Guttman-Yassky E, Dhingra N, Leung DY. New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther 2013;13:549-61. [PMID: 23323893 DOI: 10.1517/14712598.2013.758708] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 8.5] [Reference Citation Analysis]
10 Karatas Y, Erdi MF, Kaya B, Keskin F, Cüce G, Kılınc I, Uyar M, Izci EK, Kalkan E. Neuroprotective Effects of Tocilizumab on Experimentally-Induced Spinal Cord Ischemia-Reperfusion Injury. World Neurosurg 2018:S1878-8750(18)32892-4. [PMID: 30593966 DOI: 10.1016/j.wneu.2018.12.069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
11 Mizuno K, Ikeuchi-Takahashi Y, Hattori Y, Onishi H. Preparation and evaluation of conjugate nanogels of glycyl-prednisolone with natural anionic polysaccharides as anti-arthritic delivery systems. Drug Deliv 2021;28:144-52. [PMID: 33372563 DOI: 10.1080/10717544.2020.1865478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 El Kasmi KC, Pugliese SC, Riddle SR, Poth JM, Anderson AL, Frid MG, Li M, Pullamsetti SS, Savai R, Nagel MA, Fini MA, Graham BB, Tuder RM, Friedman JE, Eltzschig HK, Sokol RJ, Stenmark KR. Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension. J Immunol 2014;193:597-609. [PMID: 24928992 DOI: 10.4049/jimmunol.1303048] [Cited by in Crossref: 112] [Cited by in F6Publishing: 106] [Article Influence: 16.0] [Reference Citation Analysis]
13 Semerano L, Thiolat A, Minichiello E, Clavel G, Bessis N, Boissier M. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs. Expert Opinion on Investigational Drugs 2014;23:979-99. [DOI: 10.1517/13543784.2014.912276] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
14 Ryan SO, Johnson JL, Cobb BA. Neutrophils confer T cell resistance to myeloid-derived suppressor cell-mediated suppression to promote chronic inflammation. J Immunol 2013;190:5037-47. [PMID: 23576679 DOI: 10.4049/jimmunol.1203404] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
15 Qu D, Liu J, Lau CW, Huang Y. IL-6 in diabetes and cardiovascular complications. Br J Pharmacol. 2014;171:3595-3603. [PMID: 24697653 DOI: 10.1111/bph.12713] [Cited by in Crossref: 73] [Cited by in F6Publishing: 62] [Article Influence: 14.6] [Reference Citation Analysis]
16 Janssens K, Slaets H, Hellings N. Immunomodulatory properties of the IL-6 cytokine family in multiple sclerosis. Ann N Y Acad Sci 2015;1351:52-60. [PMID: 26100315 DOI: 10.1111/nyas.12821] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
17 McLaughlin M, Östör A. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Expert Opin Drug Saf 2015;14:429-37. [PMID: 25553607 DOI: 10.1517/14740338.2015.998198] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
18 Truchetet ME, Mossalayi MD, Boniface K. IL-17 in the rheumatologist's line of sight. Biomed Res Int 2013;2013:295132. [PMID: 23984335 DOI: 10.1155/2013/295132] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
19 Barone M, Notarnicola A, Lopalco G, Viggiani MT, Sebastiani F, Covelli M, Iannone F, Avolio AW, Di Leo A, Cantarini L. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology. 2015;62:40-46. [PMID: 25613809 DOI: 10.1002/hep.27716] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
20 Sherlock JP, Filer AD, Isaacs JD, Buckley CD. What can rheumatologists learn from translational cancer therapy? Arthritis Res Ther 2013;15:114. [PMID: 23638860 DOI: 10.1186/ar4203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
21 Markatseli TE, Theodoridou A, Zakalka M, Koukli E, Triantafyllidou E, Tsalavos S, Andrianakos A, Drosos AA. Persistence and Adherence during the First Six Months of Tocilizumab Treatment Among Rheumatoid Arthritis Patients in Routine Clinical Practice in Greece. Results from the Single Arm REMISSION II Study (NCT01649817). Mediterr J Rheumatol 2019;30:177-85. [PMID: 32185362 DOI: 10.31138/mjr.30.3.177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Sima C, Glogauer M. Macrophage subsets and osteoimmunology: tuning of the immunological recognition and effector systems that maintain alveolar bone. Periodontol 2000 2013;63:80-101. [PMID: 23931056 DOI: 10.1111/prd.12032] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 9.7] [Reference Citation Analysis]
23 Koryürek ÖM, Kalkan G. A new alternative therapy in dermatology: tocilizumab. Cutaneous and Ocular Toxicology 2016. [DOI: 10.3109/15569527.2015.1049356] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]